Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 13.
doi: 10.1007/s11096-025-01965-5. Online ahead of print.

Anticholinergic medicines - medication management, prescribing cascades, and deprescribing

Ivana Tadic  1 , Anita Elaine Weidmann  2
Affiliations

Anticholinergic medicines - medication management, prescribing cascades, and deprescribing

Ivana Tadic et al. Int J Clin Pharm. .

Abstract

This comment aims to raise awareness of the problems encountered when using anticholinergic burden (ACB) tools for the assessment of inappropriate medications (PIM), concerns related to prescribing cascades, and the process of deprescribing in patients older than 65 years. The first published tool, BEERS criteria from 1991, interpreted the ACB as the single biggest iatrogenic problem in treating older patients. Numerous subsequent publications repeated this interpretation rather than using real-world data. By comparing three internationally validated PIM tools (AGS BEERs criteria; EU(7)-PIM; PIM), this comment highlights how their anticholinergic (ACh) medicines lists differ, lack specific details on the strength of the ACh effect while also not providing suitable alternative pharmacological approaches. In addition, this comment considers the recognized contribution of ACh medicines in prescribing cascades and resultant inappropriate polypharmacy concerns while also considering barriers to deprescribing in the face of lacking detailed clinical guidance.

Keywords: Cascades; Cholinergic antagonists; Deprescriptions; Inappropriate prescribing; Patient safety.

PubMed Disclaimer

Conflict of interest statement

Declarations. Competing interest: A.E.W., is an Associate Editor of the International Journal of Clinical Pharmacy. She had no role in handling the manuscript, neither in the processes of editorial review and peer review nor in relation to decision making. The authors have no relevant financial or non-financial interests to disclose. Ethics approval: No ethics approval was needed for this comment.

Similar articles

See all similar articles

References

    1. World Health Organization. Medication Safety in Polypharmacy [Internet]. 2019. https://iris.who.int/bitstream/handle/10665/325454/WHO-UHC-SDS-2019.11-e... . Accessed 9 Apr 2025.
    1. Kurczewska-Michalak M, Lewek P, Jankowska-Polańska B, et al. Polypharmacy management in the older adults: a scoping review of available interventions. Front Pharmacol. 2021;12: 734045. - PubMed - PMC
    1. Wong HL, Weaver C, Marsh L, et al. Polypharmacy and cumulative anticholinergic burden in older adults hospitalized with fall. Aging Med. 2023;6:116–23.
    1. Dean T, Koné A, Martin L, et al. Understanding the extent of polypharmacy and its association with health service utilization among persons with cancer and multimorbidity: a population-based retrospective cohort study in Ontario. Canada J Pharm Pract. 2024;37:35–46. - PubMed
    1. Ngcobo NN. Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review. Clin Pharmacokinet. 2025;64(3):335–67. - PubMed - PMC

LinkOut - more resources